

LEADING REGENERATION

Geistlich
Biomaterials

Pace
&

Persistence

Introducing
the first
xenogeneic/allogeneic
validated bone substitute¹



Pace & Persistence – it's who we are.

Determining the right time and pace of innovation is something we have experience in – 165 years to be exact.

Geistlich Biomaterials has forged our unique path with ground breaking innovations like Geistlich Bio-Oss[®], Geistlich Bio-Gide[®] and Geistlich Fibro-Gide[®].

Now we're making it easier for you to combine two validated regenerative materials for restoring vital bone faster – with the proven long-term volume stability you rely on.

Pace is how you run the race. Persistence is how you win it.

Our commitment to product reliability and time-tested manufacturing creates a bond like no other, empowering you with treatments that are exactly what patients deserve.

EXACTLY
 like no other.

Geistlich takes pride in the quality and the safety of our products, consistently employing rigorous testing and strict manufacturing processes that exceed regulatory requirements. By selecting innovative partners who share this strong commitment, we're proud to offer Geistlich vallomix[™] as a member of the Geistlich Select product range.

**Geistlich
Select**

Osteoinductive Potential

Verified vallos™ granules and fibers are allogeneic bone substitutes that have been demineralized to ensure high osteoinductive properties¹. A demineralized bone matrix has the advantage of turning over natural bone more rapidly but lacks the volume stability needed in a number of clinical situations.

The selection process of vallos™ involves thorough review and validated lot testing to ensure:

- Consistent product quality¹
- Verified osteoinductive potential, validated test method¹
- Vital bone after 18-20 weeks²

Volume Stability

Geistlich Bio-Oss® is the leading xenogeneic bone substitute worldwide, with more than 35 years of scientific validation. It is the ideal biomaterial that consistently maintains bone volume overtime.³⁻⁸

With each vial of Geistlich Bio-Oss®, you are assured a treatment solution with:


- Demonstrated clinical success⁹
- Optimal scaffold for vascularization and new bone formation¹⁰⁻¹³
- Long-term volume stability³⁻⁸



vallos™ granules – ideally suited for smaller routine defects.



vallos™ f fibers – for larger more complex defects.




Geistlich Bio-Oss® granules are available in a variety of sizes to meet your clinical needs

Introducing Geistlich vallomix™

Validated • Allograft • Osteoinductive • Selection

Bringing together the verified osteoinductivity of vallos™ allograft¹ with the volume stability of Geistlich Bio-Oss®.³⁻⁸

Conveniently packaged Geistlich vallomix™ contains Geistlich Bio-Oss® granules and vallos™ granules or fibers. Together, these proven products bring optimal consistency and performance in demanding clinical situations.



Bone Augmentation. *Your Way.*

Mix it or layer it – Geistlich vallomix™ is innovation that works with you.

- Readily available off-the-shelf solution
- The micro and macro pore structure of Geistlich Bio-Oss® enhances the hydrophilic properties of the mixture¹⁴
- Versatility for the management of small or large defects

| vallos™ Demineralized cortical allograft | | + | Geistlich Bio-Oss® Bone grafting material | | = | Geistlich vallomix™ | |
|---|---------------------|-------------------------|--|-------------|--------|---------------------|--|
| | | | | Part Number | Size | | |
| GRANULES | 125-180 μm, 0.25 cc | 0.25 mm – 1 mm, 0.25 cc | | VMG1050 | .5 cc | | |
| | 125-180 μm, 0.5 cc | 0.25 mm – 1 mm, 0.5 cc | | VMG1100 | 1 cc | | |
| | 125-180 μm, 1 cc | 0.25 mm – 1 mm, 1 cc | | VMG1200 | 2 cc | | |
| FIBERS | 125-180 μm, 1 cc | 0.25 mm – 1 mm, 1 cc | | VMF1200 | 2 cc | | |
| | 125-180 μm, 2.5 cc | 0.25 mm – 1 mm, 2 cc | | VMF1450 | 4.5 cc | | |

Exceeding industry standards.

When combined, the strict quality standards of Geistlich Bio-Oss® and validated lot testing of vallos™ create new clinical potential.



For handling recommendations and to learn more, visit:
vallomix.geistlich-na.com



Geistlich Pharma North America, Inc.
Princeton, NJ 08540
Customer Care Toll-free: 855-799-5500
info@geistlich-na.com
dental.geistlich-na.com

Our Biomaterials Are:

Documented

More than 1,000 publications

Reliable

More than 30 years of clinical experience

Experienced

More than 165 years of Geistlich collagen competence



To learn more, visit:
vallomix.geistlich-na.com

CAUTION: Federal law restricts these devices to sale by or on the order of a dentist or physician.

For more information on contraindications, precautions, and directions for use, please refer to the Instructions for Use at:
vallomix.geistlich-na.com/ifu

References

1. Compiled DCI Osteoinductivity Validation Summary .2020. (data on file)
2. Robert A Wood & Brian L Mealey: J Periodontol. 2012 Mar;83(3):329-36. (Clinical Study)
3. Piattelli M et al.: Int J Oral Maxillofac Implants 1999; 14 (6), 835-40. (Clinical Study).
4. Sartori S et al.: Clin Oral Implants Res 2003; 14 (3), 369-72. (Clinical Study).
5. Maiorana C et al.: Int J Periodontics Restorative Dent 2005; 25 (1), 19-25. (Clinical Study).
6. Orsini G et al.: Oral Dis 2007; 13 (6), 586-93. (Clinical Study).
7. Lindgren C et al.: Int J Oral Maxillofac Implants 2009; 24 (6), 1093-100. (Clinical Study).
8. Mordenfeld A et al.: Clin Oral Implants Res 2010; 21 (9), 961-70. (Clinical Study).
9. NCBI Pubmed, Month Year, Search term "Bio-Oss" (1208 hits) (Market research).
10. Berglundh T & Lindhe J: Clin Oral Implants Res 1997; 8 (2), 117-24. (Preclinical Study).
11. Weibrich G et al.: Mund Kiefer Gesichtschir 2000; 4 (3), 148-52. (Preclinical Study).
12. Degidi M et al.: Oral Dis 2006; 12 (5), 469-75. (Clinical Study).
13. Galindo-Moreno P et al.: Clin Oral Implants Res 2010; 21 (2), 221-7. (Clinical Study).
14. Degidi M, Artese L, Rubini C, Perrotti V, Iezzi G, Piattelli A. Microvessel density and vascular endothelial growth factor expression in sinus augmentation using Bio-Oss®. Oral Dis. 2006 Sep; 12(5): 469–75.